Sign up to save your podcasts
Or
Share E49: IL17i vs. TNFi for Psoriatic Arthritis (SPIRIT-H2H)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
E49: IL17i vs. TNFi for Psoriatic Arthritis (SPIRIT-H2H)
Today I dive into the emerging therapies for psoriatic arthritis, focusing on the IL17i ixekizumab and the recently published SPIRIT-H2H trial. It's a great combination of my favorite thing in RCTs (head to head trials) and my least favorite thing in RCTs (RCTs that were designed in such a way that they don't answer the question I want to know).
View all episodes
By Michael Putman
4.9
113113 ratings
Today I dive into the emerging therapies for psoriatic arthritis, focusing on the IL17i ixekizumab and the recently published SPIRIT-H2H trial. It's a great combination of my favorite thing in RCTs (head to head trials) and my least favorite thing in RCTs (RCTs that were designed in such a way that they don't answer the question I want to know).
More shows like The Evidence Based Rheumatology Podcast
View all
NEJM This Week
323 Listeners
JAMA Clinical Reviews
499 Listeners
This Week in Cardiology
876 Listeners
Rheumnow Podcast
131 Listeners
Core IM | Internal Medicine Podcast
1,146 Listeners
Healio Rheuminations
121 Listeners
Annals On Call Podcast
192 Listeners
Freely Filtered, a NephJC Podcast
172 Listeners
ACR on Air
67 Listeners
Run the List
247 Listeners
Around the Rheum with Drs. Daniel Ennis & Janet Pope
4 Listeners
Rheumatology For The Royal College
183 Listeners
RheumMadness Rheumatology Podcast
11 Listeners
ACR Journals On Air
18 Listeners
Talking Rheumatology Spotlight
6 Listeners